The effect of Tolvaptan in hyponatremia patients with severe heart failure
ZHAO Jin
FENG Xian-zhen
FENG Li-li
SUN Ke-yuan
YANG Wei
Abstract：Objective To investigate effect of Tolvaptan in hyponatremia patients with severe heart failure. Methods 144 patients clearly diagnosed as severe heart failure with hyponatremia were selected. 82 cases were defined the treatment group with Tolvaptan plus regular treatment; 62 cases were defined as control group with only regular treatment. Minnesota Living With Heart Failure Questionnaire (MLHFQ) scores, echocardiography, ultrasound assessment indicators, including left ventricular ejection fraction (LVEF), Left Ventricular Systolic Function (LVSF), left ventricular end diastolic diameter (LVDD), left ventricular systolic dysfunction (LVSD), N-terminal prohormone of brain natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein (hs-CRP), sodium, urine output, weight, and adverse events were measured before and at 3 months after treatment.Results Blood sodium of patients in the treatment group significantly increased, and hs-CRP, NT-proBNP decreased significantly (P<0.05). As to patients in the treatment group, the cardiac function was improved significantly, the difference has statistical significance (P<0.05). Curative effect was better in treatment group than control group (93.90%vs. 80.65%,P<0.01). The MLHFQ score of treatment group improved better than that of control group (P<0.05). No adverse event of hepatic and renal function was observed.Conclusion Tolvaptan can effectively reverse the cardiac function, and correct hyponatremia with no increasing adverse reactions.
Keywords：TolvaptanSevere heart failureHyponatremiaClinical curative effect
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 1008-1010 )